Nomura Instinet analyst Christopher Marai believes Alexion Pharmaceuticals’ (ALXN) acquisition of Syntimmune highlights potential demand for FcRn therapies by acquirers and bodes well for Argenx (ARGX). The analyst keeps a Buy rating on Argenx with a $161 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.